G. Sedgh, S. Henshaw, S. Singh, E. Ahman, and I. H. Shah, Induced abortion: estimated rates and trends worldwide, Lancet Lond Engl, vol.370, pp.1338-1383, 2007.

, Unsafe Abortion: Global and Regional Estimates of the Incidence of Unsafe Abortion and Associated Mortality in 2008, 6th edn, 2011.

S. Singh and I. Maddow-zimet, Facility-based treatment for medical complications resulting from unsafe pregnancy termination in the developing world, 2012: a review of evidence from 26 countries, BJOG Int J Obstet Gynaecol, vol.123, pp.1489-98, 2015.

L. Morts-maternelles-en and F. , mieux comprendre pour mieux prévenir. 5e rapport de l'Enquête nationale confidentielle sur les morts maternelles (ENCMM), pp.2010-2012, 2017.

A. Vilain, Direction de la Recherche, des Etudes, de l'Evaluation et des Statistiques -211900 interruptions volontaires de grossesse en, 2016.

V. Bellamy, Institut National de la Statistique et des Etudes Economiques -Les naissances en, 2016.

M. Mazuy, L. Toulemon, and É. Baril, Le nombre d'IVG est stable, mais moins de femmes y ont recours, Population, vol.69, pp.365-98, 2014.

, Haute Autorité de Santé -Interruption volontaire de grossesse par méthode médicamenteuse, 2015.

H. Hamoda and A. Templeton, Medical and surgical options for induced abortion in first trimester, Best Pract Res Clin Obstet Gynaecol, vol.24, pp.503-519, 2010.

A. Vilain, Direction de la Recherche, des Etudes, de l'Evaluation et des Statistiques -Les interruptions volontaires de grossesse en, 2015.

, Autorisation -Agence nationale de sécurité du médicament et des produits de santé, 2018.

J. Aubert, T. Bejan-angoulvant, and J. , Pharmacologie du misoprostol (données pharmacocinétiques, tolérance et effets tératogènes), 2014.

P. F. Svendsen, C. Rørbye, T. Vejborg, and L. Nilas, Comparison of gemeprost and vaginal misoprostol in first trimester mifepristone-induced abortion, Contraception, vol.72, pp.28-32, 2005.

G. Beucher, P. Dolley, G. Carles, F. Salaun, I. Asselin et al., Misoprostol : utilisation hors AMM au premier trimestre de la grossesse (fausses couches spontanées, interruptions médicales et volontaires de grossesse), J Gynécologie Obstétrique Biol Reprod, vol.43, pp.123-168, 2014.

, Délivrance des spécialités Gymiso® et MisoOne® suite à l'arrêt de commercialisation de Cytotec® -Communications -Ordre National des Pharmaciens, 2018.

A. Agostini, C. Vayssière, A. Gaudineau, B. Letombe, S. Eyraud et al., Interruption volontaire de grossesse, CNGOF, 2016.

A. Faúndes and . Working, Group on Prevention of Unsafe Abortion and its Consequences, International Federation of Gynecology and Obstetrics. The combination of mifepristone and misoprostol for the termination of pregnancy, Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet, vol.115, pp.1-4, 2011.

, Safe Abortion: Technical and Policy Guidance for Health Systems. 2nd éd. Geneva: World Health Organization, 2012.

, Cytotec (misoprostol) : arrêt de commercialisation à compter du 1er mars 2018 -Communiqué -ANSM : Agence nationale de sécurité du médicament et des produits de santé. 2017. Disponible sur

J. Chai, C. Wong, and P. C. Ho, A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation, Contraception, vol.87, pp.480-485, 2013.

S. Raghavan, R. Comendant, I. Digol, S. Ungureanu, I. Dondiuc et al., Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: a randomized controlled trial, Contraception, vol.82, pp.513-522, 2010.

R. Kulier, N. Kapp, A. M. Gülmezoglu, G. J. Hofmeyr, L. Cheng et al., Medical methods for first trimester abortion, Cochrane Database Syst Rev, p.2855, 2011.

, World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation. Medical abortion at 57 to 63 days' gestation with a lower dose of mifepristone and gemeprost. A randomized controlled trial, Acta Obstet Gynecol Scand, vol.80, pp.447-51, 2001.

T. Middleton, E. Schaff, S. L. Fielding, M. Scahill, C. Shannon et al., Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period, Contraception, vol.72, pp.328-360, 2005.

H. Hamoda, P. W. Ashok, G. Flett, and A. Templeton, A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation, BJOG Int J Obstet Gynaecol, vol.112, pp.1102-1110, 2005.

S. Raghavan, R. Comendant, I. Digol, S. Ungureanu, V. Friptu et al., Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostol, Contraception, vol.79, pp.84-90, 2009.

A. Reynolds, D. Ayres-de-campos, M. A. Costa, and N. Montenegro, How should success be defined when attempting medical resolution of first-trimester missed abortion?, Eur J Obstet Gynecol Reprod Biol, vol.118, pp.71-77, 2005.

G. Condous, The management of early pregnancy complications, Best Pract Res Clin Obstet Gynaecol, vol.18, pp.37-57, 2004.

, Termination of pregnancy with reduced doses of mifepristone. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation, BMJ, vol.307, pp.532-539, 1993.

E. G. Raymond, C. Shannon, M. A. Weaver, and B. Winikoff, First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review, Contraception, vol.87, pp.26-37, 2013.

H. Von-hertzen, G. Piaggio, D. Wojdyla, L. Marions, M. Huong et al., Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial, BJOG Int J Obstet Gynaecol, vol.116, pp.381-390, 2009.

L. Wedisinghe and D. Elsandabesee, Flexible mifepristone and misoprostol administration interval for first-trimester medical termination, Contraception, vol.81, pp.269-74, 2010.

E. A. Schaff, S. L. Fielding, C. Westhoff, C. Ellertson, S. H. Eisinger et al., Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial, JAMA, vol.284, pp.1948-53, 2000.

J. Bartley, A. Brown, R. Elton, and D. T. Baird, Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation, Hum Reprod Oxf Engl, vol.16, pp.2098-102, 2001.

O. S. Tang, C. Chan, E. Ng, S. Lee, and P. C. Ho, A prospective, randomized, placebocontrolled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation, Hum Reprod Oxf Engl, vol.18, pp.2315-2323, 2003.

H. Von-hertzen, N. Huong, G. Piaggio, M. Bayalag, E. Cabezas et al., Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial, BJOG Int J Obstet Gynaecol, vol.117, pp.1186-96, 2010.

B. Winikoff, I. G. Dzuba, M. D. Creinin, W. A. Crowden, A. B. Goldberg et al., Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial, Obstet Gynecol, vol.112, pp.1303-1313, 2008.

E. Chong, T. Tsereteli, N. Nguyen, and B. Winikoff, A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion, Contraception, vol.86, pp.251-257, 2012.

M. F. Gallo, S. Cahill, L. Castleman, and E. Mitchell, A systematic review of more than one dose of misoprostol after mifepristone for abortion up to 10 weeks of gestation, Contraception, vol.74, pp.36-41, 2006.

K. Coyaji, U. Krishna, S. Ambardekar, H. Bracken, V. Raote et al., Are two doses of misoprostol after mifepristone for early abortion better than one?, BJOG Int J Obstet Gynaecol, vol.114, pp.271-279, 2007.

O. S. Tang, K. Gemzell-danielsson, and P. C. Ho, Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects, Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet, vol.99, issue.2, pp.160-167, 2007.

M. Zieman, S. K. Fong, N. L. Benowitz, D. Banskter, and P. D. Darney, Absorption kinetics of misoprostol with oral or vaginal administration, Obstet Gynecol, vol.90, pp.88-92, 1997.

O. S. Tang, H. Schweer, H. W. Seyberth, S. Lee, and P. C. Ho, Pharmacokinetics of different routes of administration of misoprostol, Hum Reprod Oxf Engl, vol.17, pp.332-338, 2002.

A. Aronsson, C. Fiala, O. Stephansson, F. Granath, B. Watzer et al., Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slowrelease oral misoprostol, Hum Reprod Oxf Engl, vol.22, pp.1912-1920, 2007.

E. A. Schaff, R. Dicenzo, and S. L. Fielding, Comparison of misoprostol plasma concentrations following buccal and sublingual administration, Contraception, vol.71, pp.22-27, 2005.

R. Khan, H. El-refaey, S. Sharma, D. Sooranna, and M. Stafford, Oral, rectal, and vaginal pharmacokinetics of misoprostol, Obstet Gynecol, vol.103, pp.866-70, 2004.

, IVG médicamenteuse : rappel des conditions d'utilisation de la mifépristone et du misoprostol -ANSM : Agence nationale de sécurité du médicament et des produits de santé. 2005. Disponible sur

M. Fischer, J. Bhatnagar, J. Guarner, S. Reagan, J. K. Hacker et al., Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion, N Engl J Med, vol.353, pp.2352-60, 2005.

E. Meites, S. Zane, C. Gould, and C. Investigators, Fatal Clostridium sordellii infections after medical abortions, N Engl J Med, vol.363, pp.1382-1385, 2010.

A. L. Cohen, J. Bhatnagar, S. Reagan, S. B. Zane, D. 'angeli et al., Toxic shock associated with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion, Obstet Gynecol, vol.110, pp.1027-1060, 2007.

S. L. Achilles and M. F. Reeves, Society of Family Planning. Prevention of infection after induced abortion: release date, SFP guideline 20102, vol.83, pp.295-309, 2010.

D. Entre,

, Introduction -Il existe de nombreux schémas médicamenteux utilisés dans l'IVG entre 7 et 9 semaines d'aménorrhée (SA). L'objectif principal de notre étude était de comparer l'efficacité des différentes voies d'administration (per-os

, Matériel et méthodes -Etude prospective, randomisée, monocentrique, comparant l'efficacité de trois voies d'administration et de deux doses du misoprostol dans l'IVG médicamenteuse entre 7 et 9SA. Notre critère de jugement principal était défini comme l'évacuation complète de la grossesse à l'échographie à trois semaines

, Le taux de succès global était de l'ordre de 72,6% pour un taux d'échec de 27,4% avec un taux de grossesses évolutives de 8,8%. Nous n'avons pas mis en évidence de différence significative entre les voies d'administration (p=0,854), 2018.

, De plus, nous avions inclus plus de femmes dans la voie per-os, alors qu'une méta-analyse de 2011 mettait en évidence une supériorité des autres voies d'administration du misoprostol par rapport à la voie orale

, Conclusion -Nous n'avons pas réussi à mettre en évidence de différence significative entre les voies d'administration et les doses du misoprostol, en raison d'un manque de puissance. Depuis le retrait du Cytotec®, se pose la question du coût des dépenses de santé liées à l'IVG

, Mots clés : Interruption volontaire de grossesse, misoprostol, Cytotec®, voie d'administration, dose RANDOMIZED PROSPECTIVE PILOT STUDY COMPARING THE DIFFERENT ROUTES OF

. Administration-and, . Of, . During, and . Abortion,

, Objective -There are many drugs regimens used in medical abortion between 7 and 9 weeks of amenorrhea (WA)

, The main objective of our study was to compare the efficacy of different routes of administration (oral, sublingual/buccal or vaginal) and doses of misoprostol

, Methods -A prospective, randomized, single-center study comparing the efficacy of three routes of administration and two doses of misoprostol in drug-induced medical abortion between 7 and 9WA. Our primary criterion of outcome was defined as complete evacuation of pregnancy on ultrasound at three weeks

, The overall success rate was of administration (p=0,854) and the dose, 2017.

, Discussion -Our success rate is low compared to other studies, however the evaluation of uterine vacuity was not always well specified in the literature. In addition, we included more women in the oral route, while a 2011 metaanalysis showed superiority of other routes of administration of misoprostol compared over the oral route